Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced plans to recognize National Diabetes Awareness Month and World Diabetes Day with a series of activities in November.

“People with diabetes must make dozens of decisions every day to manage their condition, which can be incredibly stressful, overwhelming at times, and get in the way of enjoying life. This impact often extends to family members and caregivers, a burden the general public largely underappreciates,” said Jim Hollingshead, President and Chief Executive Officer, who noted that an estimated 500 to 600 million adults are living with diabetes, which is forecasted to grow to more than 640 million by 2030. “At Insulet, where many of us have personal connections to diabetes, we all get to do something special, improving lives through our important work.”

Nasdaq Closing Bell Ceremony:

On November 12, Mr. Hollingshead, along with members from the Company’s leadership team and global employees, will be joined by five Omnipod users (Podders) from the United States, Canada, Germany, and the UK to ring the Nasdaq Stock Market closing bell at 4:00 p.m. ET. The Podders represent the hundreds of thousands of people with diabetes who use Omnipod around the world. On behalf of the five Podders and as part of the Insulet for Good initiative, the Company will make charitable contributions to diabetes organizations of their choice. The Nasdaq closing bell ceremony will be aired live on the Nasdaq website and broadcast on CNBC and MSNBC TV.

ADA Panel Discussion:

Insulet is sponsoring the American Diabetes Association’s® (ADA) two-day community event focused on empowering communities to combat diabetes and obesity on November 22 – 23 at Roxbury Community College in Boston, MA. The State of Diabetes event will include a panel discussion with Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer, on diabetes-related health equity topics such as diabetes prevention and education, access, cost of diabetes, advocacy efforts, and policy changes. Insulet will also exhibit at the ADA Community Day of Access, which includes free healthcare screenings and more.

“Insulet teams around the world are laser focused on delivering innovations and bringing research-led insights that empower people with diabetes to live their best lives,” said Dr. Ly. “We are proud to support ADA's State of Diabetes event, and I look forward to joining in the conversation and sharing our perspectives with others who also care deeply about advancing diabetes care and making the healthcare community stronger."

New Podcast Launch:

A new Insulet-sponsored podcast, “TypeCast: Life Between the Lines,” is set to launch in November. Hosted by Omnipod Ambassador Natalie Balmain, it will share different stories and life experiences of people with diabetes from around the world, one of several podcasts that Insulet supports to raise awareness.

Employee Engagement:

Throughout the month and part of Insulet for Good, employees will write notes of support and encouragement to recently diagnosed people (and their families), an effort that is being coordinated with Breakthrough T1D (formerly JDRF).

Lastly, for World Diabetes Day on November 14, the Company will host fun, informative, and interactive employee activities globally to share customer stories on various platforms to further raise awareness about diabetes and engagement around the Company’s unifying mission—to improve the lives of people with diabetes.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241101403404/en/